Reports total Q1 2026 revenue of $3.4 million, representing year-over-year growth of 122% - - Received IDE approval from FDA to initiate the CGUARDIANS III clinical trial of its SwitchGuard ...
U.S. Revenue -- $497,000, marking the first recorded U.S. commercial revenue for the company following FDA approval of CGuard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results